Besides Sibbald, additional authors of the analysis consist of Barbara Visentin, John Vekich, Amy Cavalli and Kelli Moreno, all previous SDSU students. Various other contributing researchers consist of Rosalia William and Matteo Garland, both with Lpath Inc., and University of Texas Anderson Cancer Center researchers Shuangxing Yu, Yiling Lu, Hassan Hall, Vikas Kundra and Gordon Mills. Sabbadini will present the team’s findings at the annual conference for the American Association of Cancer tumor Researchers, April 1 – 5, in Washington D.C.Most of the mothers , who had few depressive symptoms and did not use SSRIs, formed the control group. Another 570 moms had clinically relevant depressive symptoms but didn’t use SSRIs, while the remaining 99 moms used SSRIs during pregnancy. Mean depression ratings on the depression level of the Brief Symptom Inventory had been 0.10 in the control group, 1.45 in the women with depressive symptoms but no SSRIs, and 0.74 for the women taking SSRIs. They found that the untreated, depressed females were more likely to have infants with reduced body development, including reduced fetal mind size, while depressed women taking SSRIs were more likely to have babies with reduced fetal mind size but a standard fetal body growth. It’s unclear how significant decreased fetal head development is.